Angel One Retains Buy Rating on Lincoln Pharmaceuticals with 39% Upside Target
Shares of Gujarat-based Lincoln Pharmaceuticals have faced profit-booking pressure after reaching a 52-week high but remain a buy according to brokerage Angel One. The firm reported broad-based Q1 FY27 growth with core operating profit and revenue rising about 15% year-on-year, stable operating margins near 15.5%, and a 31% increase in profit after tax. Angel One set a 12-month target price of Rs 845, implying 39% upside, citing the company’s diversified portfolio, expanding international operations, and a debt-free balance sheet. However, core operating performance remains a key monitorable due to some profit from other income.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (69/100). Lens Score 37/100.
Outlets measured: moneycontrol, mint. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (68–70/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
mint broke this story on 19 Aug, 09:35 am. Other outlets followed.